Pharma casts a wide net to hook opportunities in metabolic disorders
The recent success of diabetes and weight loss medications has spurred more interest in other metabolic disorders.
07 August 2024
07 August 2024
The recent success of diabetes and weight loss medications has spurred more interest in other metabolic disorders.
Biotech IPOs were up six-fold in Q1 2024 from the previous quarter, but the current global stock market crash means a sustained rebound is in jeopardy.
Excluding sales from the Horizon acquisition, product sales of the company grew by 5%, with volume growth of 10%.
MSD will receive an upfront payment of $170m.
Sangamo could receive $1.9bn in development and commercial milestones across multiple products.
Vocacapsaicin has demonstrated significant pain relief and early opioid cessation post-surgery in Phase II clinical trials.
The China-headquartered CDMO is planning to scale its manufacturing operations, expand its presence in APAC, and set up a Swiss subsidiary.
The FDA's approval is based on the data from the Phase III INDIGO clinical trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.